Cowan NC CT urography for hematuria. Nat Rev Urol. 2012 Mar 13;9(4):218-26. doi: 10.1038/nrurol.2012.32.
Davidson PJ, McGeoch G, Shand B Assessment of a clinical pathway for investigation of haematuria that reduces the need for cystoscopy. N Z Med J. 2020 Dec 18;133(1527):71-82.
Freudenberg LS, Beyer T Subjective perception of radiation risk. J Nucl Med. 2011 Dec;52 Suppl 2:29S-35S. doi: 10.2967/jnumed.110.085720.
Inman BA, Tran VT, Fradet Y, Lacombe L Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality. Cancer. 2009 Jul 1;115(13):2853-62. doi: 10.1002/cncr.24339.
Jocham D, Stepp H, Waidelich R Photodynamic diagnosis in urology: state-of-the-art. Eur Urol. 2008 Jun;53(6):1138-48. doi: 10.1016/j.eururo.2007.11.048. Epub 2007 Dec 10.
Johannes JR, Nelson E, Bibbo M, Bagley DH Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance. J Urol. 2010 Sep;184(3):879-82. doi: 10.1016/j.juro.2010.05.023.
Kavalieris L, O'Sullivan PJ, Suttie JM, Pownall BK, Gilling PJ, Chemasle C, Darling DG A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma. BMC Urol. 2015 Mar 27;15:23. doi: 10.1186/s12894-015-0018-5.
Koya M, Osborne S, Chemasle C, Porten S, Schuckman A, Kennedy-Smith A An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer. BMC Urol. 2020 Feb 11;20(1):12. doi: 10.1186/s12894-020-0583-0.
Linet MS, Kim KP, Rajaraman P Children's exposure to diagnostic medical radiation and cancer risk: epidemiologic and dosimetric considerations. Pediatr Radiol. 2009 Feb;39 Suppl 1(Suppl 1):S4-26. doi: 10.1007/s00247-008-1026-3. Epub 2008 Dec 16.
McHale T, Ohori NP, Cieply KM, Sherer C, Bastacky SI Comparison of urinary cytology and fluorescence in situ hybridization in the detection of urothelial neoplasia: An analysis of discordant results. Diagn Cytopathol. 2019 Apr;47(4):282-288. doi: 10.1002/dc.24108. Epub 2018 Nov 12.
Mettler FA Jr, Huda W, Yoshizumi TT, Mahesh M Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology. 2008 Jul;248(1):254-63. doi: 10.1148/radiol.2481071451.
Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, N'Dow J, Nabi G, Cook J, Vale L Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess. 2010 Jan;14(4):1-331, iii-iv. doi: 10.3310/hta14040.
Raman JD, Messer J, Sielatycki JA, Hollenbeak CS Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU Int. 2011 Apr;107(7):1059-64. doi: 10.1111/j.1464-410X.2010.09675.x. Epub 2010 Sep 3.
Royal HD Effects of low level radiation-what's new? Semin Nucl Med. 2008 Sep;38(5):392-402. doi: 10.1053/j.semnuclmed.2008.05.006.
VandenBussche CJ, Allison DB, Gupta M, Ali SZ, Rosenthal DL A 20-year and 46,000-specimen journey to Paris reveals the influence of reporting systems and passive peer feedback on pathologist practice patterns. Cancer Cytopathol. 2018 Jun;126(6):381-389. doi: 10.1002/cncy.22006. Epub 2018 May 14.
An Observational Study of Cxbladder Performance for Detection or Rule-out of Upper Tract Urothelial Cancer
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.